Relmada Therapeutics (RLMD) Amortization of Deferred Charges (2014 - 2017)

Relmada Therapeutics (RLMD) reported Amortization of Deferred Charges of $2819.0 for Q3 2017, down 96.42% quarter-over-quarter from $78724.0 in Q2 2014.

Relmada Therapeutics (RLMD) Amortization of Deferred Charges (2014 - 2017) Analysis & Trends

Relmada Therapeutics (RLMD) has 2 years of Amortization of Deferred Charges data on file, last reported at $2819.0 in Q3 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Relmada Therapeutics 581.07 Mn 581.07 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2017 2,819.00
Sep 30, 2017 2,819.00
Jun 30, 2014 78,724.00
Jun 30, 2014 78,724.00
Mar 31, 2014 65,760.00
Mar 31, 2014 65,760.00